The content on this site is intended for healthcare professionals only
At a press conference at ASCO 2014, Prof Eggermont talks about the initial efficacy and safety results from the EORTC 18071 phase III trial which looked at the use of ipilimumab versus placebo after complete resection of stage III melanoma.
Read the article for more.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Gynaecological cancer: New targets and immunotherapy developments
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
The current status of multiple myeloma diagnosis and treatment
